Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$0.6751
-0.09-11.24%
At close: -
$0.6886
0.012.00%
After Hours: Apr 4, 6:16 PM EDT
Comments
Loading...
Cue Biopharma Analyst Ratings and Price Targets | NASDAQ:CUE | Benzinga
Cue Biopharma Inc has a consensus price target of $5.29 based on the ratings of 7 analysts. The high is $10 issued by Oppenheimer on April 9, 2024. The low is $2 issued by Citizens Capital Markets on April 2, 2025. The 3 most-recent analyst ratings were released by Citizens Capital Markets, Stifel, and JMP Securities on April 2, 2025, August 20, 2024, and July 26, 2024, respectively. With an average price target of $2.67 between Citizens Capital Markets, Stifel, and JMP Securities, there's an implied 287.26% upside for Cue Biopharma Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Citizens Capital Markets
Stifel
JMP Securities
Piper Sandler
Oppenheimer
1calculated from analyst ratings
Analyst Ratings for Cue Biopharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/02/2025 | Buy Now | 190.44% | Citizens Capital Markets | Reni Benjamin45% | $2 → $2 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 08/20/2024 | Buy Now | 480.89% | Stifel | Stephen Willey50% | $8 → $4 | Maintains | Buy | Get Alert |
| 07/26/2024 | Buy Now | 190.44% | JMP Securities | Reni Benjamin45% | $15 → $2 | Maintains | Market Outperform | Get Alert |
| 07/26/2024 | Buy Now | 335.67% | Piper Sandler | Edward Tenthoff51% | $8 → $3 | Maintains | Overweight | Get Alert |
| 04/09/2024 | Buy Now | 1061.78% | Stifel | Stephen Willey50% | $8 → $8 | Maintains | Buy | Get Alert |
| 04/09/2024 | Buy Now | 1352.22% | Oppenheimer | Leland Gershell67% | $10 → $10 | Maintains | Outperform | Get Alert |
| 04/03/2024 | Buy Now | 1061.78% | Piper Sandler | Edward Tenthoff51% | $8 → $8 | Reiterates | Overweight → Overweight | Get Alert |
| 03/13/2024 | Buy Now | 771.33% | Jefferies | Maury Raycroft31% | → $6 | Initiates | → Buy | Get Alert |
| 11/06/2023 | Buy Now | 1061.78% | Piper Sandler | Edward Tenthoff51% | $7 → $8 | Maintains | Overweight | Get Alert |
| 06/26/2023 | Buy Now | 1352.22% | Oppenheimer | Mark Breidenbach47% | → $10 | Assumes | Outperform → Outperform | Get Alert |
| 06/15/2023 | Buy Now | 1061.78% | Stifel | Stephen Willey50% | → $8 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2023 | Buy Now | 2078.33% | JMP Securities | Reni Benjamin45% | → $15 | Reiterates | Outperform → Outperform | Get Alert |
| 03/22/2023 | Buy Now | 1061.78% | Stifel | Stephen Willey50% | $9 → $8 | Maintains | Buy | Get Alert |
| 03/22/2023 | Buy Now | 1352.22% | Oppenheimer | Mark Breidenbach47% | → $10 | Reiterates | → Outperform | Get Alert |
| 11/21/2022 | Buy Now | 916.56% | Piper Sandler | Edward Tenthoff51% | → $7 | Initiates | → Overweight | Get Alert |
| 08/24/2022 | Buy Now | 1352.22% | Oppenheimer | Mark Breidenbach47% | $26 → $10 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Cue Biopharma (CUE) stock?
The latest price target for Cue Biopharma (NASDAQ:CUE) was reported by Citizens Capital Markets on April 2, 2025. The analyst firm set a price target for $2.00 expecting CUE to rise to within 12 months (a possible 190.44% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cue Biopharma (CUE)?
The latest analyst rating for Cue Biopharma (NASDAQ:CUE) was provided by Citizens Capital Markets, and Cue Biopharma reiterated their market outperform rating.
When was the last upgrade for Cue Biopharma (CUE)?
There is no last upgrade for Cue Biopharma
When was the last downgrade for Cue Biopharma (CUE)?
There is no last downgrade for Cue Biopharma.
When is the next analyst rating going to be posted or updated for Cue Biopharma (CUE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cue Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cue Biopharma was filed on April 2, 2025 so you should expect the next rating to be made available sometime around April 2, 2026.
Is the Analyst Rating Cue Biopharma (CUE) correct?
While ratings are subjective and will change, the latest Cue Biopharma (CUE) rating was a reiterated with a price target of $2.00 to $2.00. The current price Cue Biopharma (CUE) is trading at is $0.69, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.